COMMUNIQUÉS West-GlobeNewswire

Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
08/05/2024
Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of $66.8 Million, a 16.2% [...]
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
08/05/2024
Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024 ASCO Annual Meeting; preparing for a potential phase 3 trial Zeno BLA accepted for priority review by the FDA for the [...]
Dentsply Sirona to Participate in Upcoming Investor Conferences
08/05/2024
CHARLOTTE, N.C., May 08, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced its participation at upcoming conferences. Bank of America 2024 Health Care [...]
Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference
08/05/2024
ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space [...]
Precision Optics Corporation Schedules Third Quarter of Fiscal Year 2024 Conference Call for Wednesday, May 15, 2024
08/05/2024
GARDNER, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense [...]
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
08/05/2024
- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting [...]
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
08/05/2024
- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial signs of efficacy [...]
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
08/05/2024
- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW, Calif., May 08, 2024 [...]
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
08/05/2024
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, currently enrolling End-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis [...]
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
08/05/2024
Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF trial in Dry Eye [...]
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
08/05/2024
ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 [...]
Anika Announces CFO Transition
08/05/2024
Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024 BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention [...]
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
08/05/2024
Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 PHILADELPHIA, May 08, 2024 (GLOBE NEWSWIRE) -- Context [...]
Cytek Biosciences Reports First Quarter 2024 Financial Results
08/05/2024
FREMONT, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first [...]
Supernus Announces First Quarter 2024 Financial Results
08/05/2024
Net sales of Qelbree ® increased 75% to $45.1 million compared to first quarter 2023. Total revenues were $143.6 million. Total revenues excluding Trokendi XR ® and Oxtellar XR ® net product sales (non-GAAP) (1) [...]
Seer Reports First Quarter 2024 Financial Results
08/05/2024
Demonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publications REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life [...]
Anika Reports First Quarter 2024 Financial Results
08/05/2024
Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million, up over 75% at the [...]
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
08/05/2024
TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate principal amount of [...]
Terns Pharmaceuticals Announces Leadership Changes
08/05/2024
FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]

Pages